Victory Capital Management
TYRA icon

Victory Capital Management’s Tyra Biosciences TYRA Stock Holding History

Victory Capital Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.87M Buy
152,585
+137,355
+902% +$4.54M ﹤0.01% 1374
2026
Q1 		$583K Sell
15,230
-3,560
-19% -$115K ﹤0.01% 1996
2025
Q4 		$494K Hold
18,790
– – ﹤0.01% 2021
2025
Q3 		$263K Sell
18,790
-25,400
-57% -$290K ﹤0.01% 2169
2025
Q2 		$423K Sell
44,190
-11,960
-21% -$114K ﹤0.01% 2087
2025
Q1 		$522K Sell
56,150
-490
-0.9% -$6.34K ﹤0.01% 2020
2024
Q4 		$787K Buy
56,640
+26,560
+88% +$482K ﹤0.01% 1901
2024
Q3 		$707K Sell
30,080
-17,080
-36% -$359K ﹤0.01% 1908
2024
Q2 		$754K Sell
47,160
-930
-2% -$16K ﹤0.01% 1827
2024
Q1 		$789K Sell
48,090
-2,130
-4% -$34.9K ﹤0.01% 1842
2023
Q4 		$696K Buy
50,220
+17,490
+53% +$226K ﹤0.01% 1873
2023
Q3 		$451K Sell
32,730
-360
-1% -$5.34K ﹤0.01% 2018
2023
Q2 		$564K Sell
33,090
-670
-2% -$9.72K ﹤0.01% 1930
2023
Q1 		$543K Buy
+33,760
New +$402K ﹤0.01% 1971

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Victory Capital Management's TYRA Position: Q2 2026 in Review

Victory Capital Management increased its Tyra Biosciences (TYRA) stake by 902% in Q2 2026, buying an estimated $4.54M and bringing the position to 152,585 shares worth $4.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1374.

Victory Capital Management first reported a position in TYRA in Q1 2023 and has held it in 14 quarters since. 168 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Victory Capital Management held 152,585 shares of Tyra Biosciences worth $4.87M as of Q2 2026.
  • Victory Capital Management bought 137,355 Tyra Biosciences shares in Q2 2026, an estimated $4.54M.
  • Tyra Biosciences made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1374 holding.
  • Victory Capital Management first reported a position in Tyra Biosciences in Q1 2023 and has held it in 14 quarters since.
  • 168 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.